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LeishmaniasisThemost effective medicines available for the treatment of leishmaniasis, a life-threatening disease, exhibit seri-
ous toxicological issues. To achieve better therapeutic efﬁciency while decreasing toxicity associated with
amphotericin B (AmB), water-soluble dextrin-AmB (Dex-AmB) formulations were developed. Self-assembled
nanocomplexeswere formed by dissolvingDex and AmB in alkaline borate buffer, followed by dialysis and either
freeze-drying (FD) or nano spray-drying (SD), yieldingwater dispersible particles with a diameter of 214 nm and
347 nm, respectively. The very simple production process allowed the formation of amorphous inclusion com-
plexes containing 14% of AmB in the form of monomers and water-soluble aggregates. Nanocomplexes were ef-
fective against parasites in axenic culture (IC50 of 0.056 and 0.096 μM for L. amazonensis and 0.030 and 0.044 μM
for L. infantum, respectively for Dex-AmB FD and Dex-AmB SD) and in decreasing the intramacrophagic infection
with L. infantum (IC50 of 0.017 and 0.023 μM, respectively for Dex-AmB FD and Dex-AmB SD). Also, the formula-
tions were able to signiﬁcantly reduce the cytotoxicity of AmB. Overall, this study demonstrates the suitability of
dextrin as an AmB carrier and the facile and inexpensive development of a delivery system for the treatment of
leishmaniasis.
© 2020 Elsevier B.V. All rights reserved.1. Background
Leishmaniasis has been classiﬁed as one of the most neglected trop-
ical morbidity and mortality causing diseases [1]. In fact, about 12–15
million people are currently infected and 350million people in 89 coun-
tries mainly in tropical and subtropical areas live at risk of developing
one of the many forms of the disease [1–3]. Protozoan parasites of the
genus Leishmania, which are responsible for this life-threateningdisease
[4], can maintain their life cycle through transmission between two
forms: the extracellular motile promastigote that multiplies in the gut
of Phlebotomus and/or Lutzomyia sandﬂies [4,5], and the intracellulararrow-derived macrophages; CC50, c
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internal organs causing visceral leishmaniasis (associated to approxi-
mately 70,000 deaths per year) [2,6].
Despite the well-established knowledge and the recent advance in
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tant parasites. Besides, as there are currently no effective vaccines to
prevent human leishmaniasis, the cure relies on chemotherapy, using
drugs of high toxicity, low efﬁcacy and difﬁcult to administer due to
low solubility [2,8]. Amphotericin B (AmB) interacts with cell mem-
brane sterols promoting cell death [9–11]. This drug is recommended
as a second-line treatment for visceral and mucocutaneous leishmania-
sis, but it presents toxicity and side effectsmainly related to the kidneys,
central nervous systemand liver [8]. Strategies to overcome these short-
comings, such as combination therapy, modiﬁcation of AmB or drug de-
livery systems have been the cornerstones to improve the therapeutic
efﬁcacy and reduce the toxicity. Some marketed AmB-based products
are available (e.g. Fungizone® and Ambisome®) which, despite higher
efﬁciency, still raise concerns regarding toxicity and high production
costs [8,12]. Therefore, it is of urgent need the development of alterna-
tive effective strategies to facilitate use of AmB for leishmaniasis
treatment.
Different polymers have been widely used as drug carriers [13]. In
fact, polysaccharides (e.g. arabinogalactan [8,14,15], dextran [16,17],
gum arabic [18], sodium alginate [19], pectin [20], galactomannan
[21]) and synthetic polymers (e.g. polymannose [22] and polyglucose
[23]) bearing highwater-solubility, low toxicity, a high degree of biode-
gradability and biocompatibility [15], have attracted considerable atten-
tion in recent years for producing water-soluble polymer-drug
formulations. Besides drug targeting, the use polysaccharides enhances
drug solubility and stability, allowing prolonged circulation lifetime and
activity and reduction of drug toxicity [8]. Nevertheless, most of the
polysaccharide-based AmB formulations reported in literature are pre-
pared by reductive amination where polysaccharides are oxidized to
render di-aldehyde derivatives reactive with AmB via Schiff base
(imine bond) or via amine bond (reduction) [14]. In this work, we hy-
pothesize that dextrin, a class of low molecular weight carbohydrates,
may be used for development of an AmB drug delivery system as it is
biocompatible, non-immunogenic and degradable in vivo by amylases
[24]. Further, we demonstrate that time consuming and complex steps
involving a pre-oxidation of the polysaccharides are not required to ob-
tain a polysaccharide-AmB formulation.We show that by simplymixing
and processing new water-soluble dextrin-amphotericin B (Dex and
AmB) in a freeze-drier or spray-dyer, Dex-AmB nanocomplexes with a
promising role in the treatment of leishmaniasis can be produced.2. Material and methods
2.1. Reagents
Amphotericin B (AmB, molecular weight of 924.08 g/mol) powder
from Streptomyces sp., resazurin Sodium salt, 4′,6-diamidino-2-
phenylindole (DAPI), triton X-100, paraformaldehyde, Schneider's In-
sect medium, sodium tetraborate decahydrate, potassium bromide,
phenol red and hemin were purchased from Sigma-Aldrich (Missouri,
USA). Dextrin Tackidex® (medical grade dextrin from potato starch)
with a degree of polymerization (DP) of 16 glucose residues and a
branching degree of 9% was a gift from Roquette (Lestrem, France).
Dulbecco's Modiﬁed Eagle Medium (DMEM), fetal bovine serum (FBS)
and penicillin-streptomycin were obtained fromMerckMillipore (Mas-
sachusetts, USA). Roswell Park Memorial Institute (RPMI) 1640
Glutamax supplemented medium and L-glutamine (GlutaMAX™-I)
was purchased from Gibco (Massachusetts, USA). Dimethylsulfoxide
(DMSO ATCC® 4-X™) solution for cell culture was acquired from
American Type Culture Collection (ATCC, Virginia, USA). Dialysis tubing
with a molecular weight cut-off of 1000 Da was obtained from Orange
Scientiﬁc (Braine-l'Alleud, Belgium). High-content screening (HCS)
CellMask™ Deep Red stain was acquired from Invitrogen (California,
USA). Acetonitrile and Formic acid were purchased from Fisher Scien-
tiﬁc (New Hampshire, USA).Please cite this article as: R. Silva-Carvalho, J. Fidalgo, K.R. Melo, et al., Dev
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Before the procedure, 1.5 g of dextrin (apparentmolecularweight of
4.5 kDa [24]) was diluted in distilled water (dH2O) at a concentration of
10mg/mL, dialyzed using a dialysis membranewith amolecularweight
cut-off 1000 Da against dH2O for 72 h and then freeze-dried. Freeze-
dried dextrin (Dex) was mixed with amphotericin B (AmB) in a mass
ratio of 4:1 and dissolved in 32 mL of 0.1 M borate buffer (pH 11),
resulting in a ﬁnal concentration of 2.5 mg/mL of AmB in the solution.
The mixture, protected from light, was gently stirred at 4 °C for 48 h
and then dialyzed at 4 °C against dH2O using amembranewith amolec-
ular weight cut-off 1000 Da. During this process, the pHwas kept at±6.
Afterward, the solutionwas freeze-dried (Coolsafe 100-9 Pro, Labogene,
Allerød, Denmark) to obtain a yellow-orangematerial (Dex-AmB FD) or
processed in a Nano Spray Dryer B-90 HP (Büchi Labortechnik AG,
Flawil, Switzerland), yielding a yellow-orange powder (Dex-AmB SD).
Brieﬂy, in the latter case the solution was fed into the instrument by a
peristaltic pump and sprayed using a piezoelectric nebulizer, operated
at a vibrational frequency of 120 kHz, with mean micron-sized pores
of 2–25 μm. The feeding rate was set to 40%, where the gas ﬂow rate
was adjusted at 10 L/min. The inlet temperature was 120 °C. The ob-
tained powder was separated, collected from the drying chamber and
stored at 4 °C in a recipient containing silica gel. Dex without AmB
was also processed by freeze-drying (Dex FD) or nano spray-drying
(Dex SD), to be tested as control.
2.3. Dex-AmB characterization
2.3.1. Nanoparticle tracking analysis (NTA)
Size of the nanocomplexes was measured by the laser-scattering
technique Nanoparticle Tracking Analysis (NTA) using a NanoSight NS
500 (Malvern Instruments Ltd., Worcestershire, UK) equipped with a
sample chamber and a 640nm laser. The produced material was dis-
solved at 1 mg/mL in dH2O. The solutions (0.3 mL) were introduced in
the sample chamber and analyzed for 60 s, using manual shutter and
gain adjustments. Measurements were performed in triplicate at room
temperature and the NTA 2.3 Build 0017 software (Malvern) was used
to collect the data.
2.3.2. Zeta potential
The zeta potential of Dex-AmB nanocomplexes was estimated by
Dynamic Light Scattering (DLS) using a Zetasizer NanoZS, (Malvern In-
struments Ltd., Worcestershire, UK). Three measurements of each solu-
tion were performed and the zeta potential values were determined
using Henry's equation [25].
2.3.3. Morphology analysis
2.3.3.1. Scanning electron cryomicroscopy (Cryo-SEM). Dex-AmB
nanocomplexes were dispersed in dH2O at a concentration of
2 mg/mL and rapidly cooled plunging it into sub-cooled nitrogen. The
samples were transferred under vacuum to the cryo stage (Gatan, Alto
2500, UK) and then fractured and sublimated for 120 s at−90 °C to re-
move the superﬁcial ice layer and allow the exposure of the
nanocomplexes. Then, the samples were sputter-coated with gold and
palladium for 45 s and transferred to the observation chamber of an
electron microscope (SEM/EDS: JEOL JSM 6301F/Oxford Inca Energy
350 from the Laboratory for Scanning Electron Microscopy and X-ray
Microanalysis at Materials Centre of the University of Porto (CEMUP)).
The observation was performed at−150 °C and 15 kV.
2.3.3.2. Scanning electron microscopy (SEM). The powder material pro-
duced in the nano spray dryer was observed using a scanning electron
microscopy (SEM; FEI Quanta 650 FEG Environmental, Field Electron
and Ion Company, Oregon, USA). Samples were ﬁxed using a double-
sided electrically conductive carbon adhesive tape (PELCO Tabs™,elopment of dextrin-amphotericin B formulations for the treatment of
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a 20 Å gold layer. Images were obtained at an excitation voltage of 5 kV.
2.3.4. HPLC-PDA-MS analysis
The HPLC system Finnigan LXQ from ThermoElectron Corporation
(Thermo Fisher Scientiﬁc, Massachusetts, USA) equipped with a Sur-
veyor Autosampler (Thermo ﬁsher Scientiﬁc, Massachusetts, USA) was
used to quantify the AmBcontent in the producedmaterials. The analyt-
ical column used was a Kinetex® C18 100 Å 100 × 4.6 mm (2.6 μmpar-
ticle size) from Phenomenex (California, USA) and the analysis was
performed using an ion trap Mass Spectrometer (MS) equipped with
an ElectroSpray Ionization (ESI) source (Thermo Fisher Scientiﬁc, Mas-
sachusetts, USA) and a 2998 photodiode array (PDA)wavelength detec-
tor (Waters Corporation, Massachusetts, USA). The MS analysis was
operated using Selected Ion Monitoring (SIM) Mode with scan ranges
from 923 to 925m/z, and the instrument was operated in positive ioni-
zation mode. The UV detection wavelengths were deﬁned to 387 and
408 nm. The mobile phase was composed by two ﬁltered and degassed
solvents: (A) ultrapure water with 0.1% (v/v) formic acid and
(B) acetonitrile with 0.1% (v/v) formic acid. The solvent gradient started
with 80% A and 20% B, reaching 10% A and 90% B at 15 min and 80% A
and 20% B at 25 min, condition that was maintained until the end of
the analysis. The run time was 30 min, with a ﬂow rate of 0.3 mL/min
and the analysis was performed at a 25 °C with a sample injection vol-
ume of 25 μL. Moreover, the source dependent parameters such as
Sheath Gas ﬂow rate, Auxiliar Gas ﬂow rate, Sweep Gas ﬂow rate,
Tube Lens, Capillar Voltage, Capillar Temperature and Spray Voltage
were optimized to 50, 10, 10, 115 V, 29 V, 250 °C and 5000 V, respec-
tively. All spectral data was acquired and analyzed using Xcalibur Chro-
matography Software (Thermo Fisher Scientiﬁc, Massachusetts, USA).
The stock standard solution of AmB (150 μg/mL) and Dex-AmB
nanocomplexes (3 mg/mL) were prepared by dissolving 6 and 9 mg of
each material in 40 and 3 mL of acetonitrile:ultrapure water:formic
acid (39.22:58.33:2.45% (v/v)) respectively, under mild stirring and
protected from light during 2 h at room temperature. Subsequently,
the calibration curves were obtained using seven standard solutions
for theMS analysis - 2, 5, 10, 20 60, 80 and 120 μg/mL - andﬁve standard
solutions for the UV analysis - 0.5, 1, 2, 10 and 20 μg/mL - andwere pre-
pared from the stock standard solution using acetronitrile:ultrapure
water (39.22:60.78% (v/v)). Similarly, for theDex-AmBnanocomplexes,
solutions of 25, 50 and 100 μg/mL were prepared using the above-
mentioned solvent. Prior to injection, standards and samples were ﬁl-
tered through a 0.22 μm pore size Nylon ﬁlter (Tecnocroma, Caldas da
Rainha, Portugal). A linear regression was used to determine slopes, in-
tercepts and correlation coefﬁcients. The percentage of drug association
efﬁciency (AE %) as well as the drug content (% w/w) in the produced
nanocomplexes were determined using the following equations, re-
spectively:
AE %ð Þ ¼ mAmB
mAmB initial
 100 ð1Þ
AmB Content %ð Þ ¼ mAmB
mDex−AmB
 100 ð2Þ
where mAmB_initial is the initial mass of AmB used in the process,mAmB is
the AmB mass in the ﬁnal formulation that was obtained via HPLC-MS
and HPLC-PDA analysis andmDex−AmB is the ﬁnal mass of the produced
material.
2.3.5. Fourier-transform infrared spectroscopy (FTIR)
FTIR spectroscopic studies of free-AmB, Dex FD, Dex SD,Dex-AmB FD
and Dex-AmB SD were carried out employing an ABB Bomem
FTLA2000-104 spectrophotometer (Québec, Canada). About 2 mg of
the different sampleswasmixedwith 200mgof dry potassiumbromide
to obtain a solid pellet. Samples were examined at transmission modePlease cite this article as: R. Silva-Carvalho, J. Fidalgo, K.R. Melo, et al., Dev
Leishmaniasis, , https://doi.org/10.1016/j.ijbiomac.2020.03.019and 64 scans were co-added for each spectrum over a wavenumber
range of 4000–700 cm−1.
2.3.6. Differential scanning calorimetry (DSC)
DSC thermograms of AmB, Dex FD, Dex SD, Dex-AmB FD and Dex-
AmB SD were obtained by using a DSC 600 Perkin-Elmer (Massachu-
setts, USA). An empty aluminum pan was used to calibrate the appara-
tus. A known amount of samples equivalent to 0.7 mg of AmB were
weighed and hermetically sealed in standard aluminum pans. Samples
were scanned from 25 to 235 °C at a ramp speed of 10 °C/min under ni-
trogen purge with a ﬂow rate of 20 mL/min. All samples were analyzed
in triplicate.
2.3.7. Powder X-ray diffraction (PXRD)
PXRD patterns of the dried samples (AmB, Dex FD, Dex SD, Dex-AmB
FD and Dex-AmB SD) were recorded using a PANalytical X'Pert Pro X-
ray diffractometer equipped with X'Celerator detector and secondary
monochromator (Malvern Panalytical, United Kingdom). For the analy-
sis, the samples were placed in a Bragg-Bentano geometry and scanned
from 7° to 50° 2θ angular range using a Cu Kα radiation (40 kV operat-
ing voltage; 30 mA current).
2.3.8. Spectrophotometric analysis of Dex-AmB nanocomplexes
AmB and Dex-AmB nanocomplexes were analyzed by UV–vis spec-
troscopy in the range of 300–450 nm using a UV–visible spectropho-
tometer (JASCO V-560 series, Jasco Inc., Maryland, USA) operated at a
band width of 5 nm, data pitch of 1 nm and scanning speed of
400 nm/min. The nanocomplexes were dissolved in dH2O at the ﬁnal
AmB concentration of 144 μM (1 mgnanocomplex/mL) and then, to avoid
spectrum saturation, samples were diluted to 10 μM using dH2O. A
stock solution of AmB at 1082 μM (1 mg/mL) was prepared using
0.1 M borate buffer pH 11. Then, as performed for the nanocomplexes,
this solution was diluted to 10 μM using dH2O. A volume of 200 μL of
the solutions was used for the measurements in a quartz cuvette. The
ratio of the absorbance of peak I (315–350) to the peak IV (408–410)
was used to monitor the aggregation state of AmB.
2.4. In vitro assays
2.4.1. Culture of Leishmania parasites
Leishmania infantum promastigotes (MHOM/MA/67/ITMAP-263)
were cultured in RPMI 1640 Glutamax supplemented with 10% (v/v)
iFBS, 50 U/mL penicillin, 50 μg/mL streptomycin and 20 mM HEPES
pH 7.4 (complete RPMI medium). Leishmania amazonensis
promastigotes (MHOM/BR/LTB0016) were cultured in Schneider's In-
sect medium supplemented with 10% (v/v) heat inactivated FBS
(iFBS), 100 U/mL penicillin, 100 μg/mL streptomycin, 5 mM HEPES
pH 7.4 and 5 μg/mL phenol red (complete Schneider's insect medium).
Both parasite strains were cultured at 25 °C. Infectivity was secured as
previously described by Gomes-Alves et al. [26].
Axenic amastigotes of L. infantumwere obtained as described in the
literature [27]. Axenic L. infantum amastigotes were derived from the
above referred strain by maintaining the culture at 37 °C with 5% CO2
in MAA/20 medium (medium for axenically grown amastigotes) sup-
plemented with 20% (v/v) iFBS, 2 mM L-Glutamine and 0.023 mM
hemin. Purity, assessed by microscopy on the basis of morphology
(round and immobile organisms, about 2–3 μm and without visible ﬂa-
gella), was around 95%.
2.4.2. Effect of Dex-AmB against axenic parasite cultures
L. infantum (3 days culture) and L. amazonensis (5 days culture) axe-
nic promastigotes, at a late exponential phase of growth,were seeded in
96-well plates using complete RPMI medium or complete Schneider's
Insect medium, respectively, at a density of 3 × 105 cells/well. Then, in-
creasing concentrations of free-AmB, Dex FD and SD and Dex-AmB FD
and SD (0.0029, 0.0059, 0.0117, 0.0234, 0.0469, 0.0938, 0.1875, 0.375elopment of dextrin-amphotericin B formulations for the treatment of
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1 °C, were added to the wells and the plates were incubated for 24 h at
26 °C. Parasite viability was assessed by resazurin assay. Brieﬂy, 20 μL of
a 2.5mM resazurin solution freshly prepared in phosphate buffer saline
pH 7.4 and ﬁltered using sterile 0.22 μm pore ﬁlters was added to each
well and then the plates were incubated for 24 h at 26 °C. Fluorescence
intensity was measured (λex 560/λem 590) in a SpectraMAX GeminiXS
microplate reader (Molecular Devices LLC, California, USA). The results
were expressed as the mean percentage ± SD of viable parasites rela-
tively to control condition (considered as 100% viability). The half max-
imal inhibitory concentration (IC50) was calculated by nonlinear
regression analysis using the GraphPad Prism software. The assay was
performed in triplicate at least three times.
2.4.3. Cell lines and cell culture
Mouse ﬁbroblast L929 cell line was purchased from American Type
Culture Collection (ATCC, Virginia, USA), Human brain microvascular
endothelial cell line (HBMEC) was kindly provided by Dr. Rui M. Reis
(ICVS/3B's-PT Government Associate Laboratory, Braga, Portugal and
Barretos Cancer Hospital, São Paulo, Brazil) and Human embryonic kid-
ney (HEK293T) cell line was kindly provided by Dr. Tiago dos Santos
(i3S - Instituto de Investigação e Inovação em Saúde, Universidade do
Porto, Portugal; INEB - Instituto de Engenharia Biomédica, Universidade
do Porto, Portugal). Both cell lines were maintained in Dulbecco's mod-
iﬁed essential medium (DMEM) supplemented with 10% (v/v) iFBS and
1% (v/v) Penicillin (10,000 U/mL)-Streptomycin (10,000 μg/mL) (com-
plete DMEMmedium) at 37 °C and 5% CO2.
2.4.4. Bone marrow-derived macrophages (BMMΦ) differentiation
Mouse bone marrow cells were differentiated in vitro according to
previous reported methods with some modiﬁcations [28]. C57BL/6
mice were anesthetized using a CO2 chamber and euthanized by cervi-
cal dislocation. Femurs and tibias were removed and cleaned in aseptic
conditions. Bones were disconnected by the articulations and then
ﬂushed using complete DMEM medium. The obtained cell suspension
of bone marrow cells was centrifuged (300 ×g, 10 min) and the pellet
re-suspended in 15 mL of complete DMEM medium supplemented
with 20% (v/v) L929-cell conditionedmedium(LCCM) as source ofmac-
rophage colony-stimulating factor (M-CSF). Bonemarrowwas cultured
overnight at 37 °C in a 5% CO2 atmosphere. The non-adherent cells were
collectedwithwarm complete DMEMmedium supplementedwith 20%
(v/v) LCCM, plated in a 96-well plate and incubated once again at 37 °C
in a 5% CO2 atmosphere. On the 4th and 7th days the half of themedium
was renewed and on the 10th day cells became fully differentiated into
macrophages.
2.4.5. Cell viability assay
The cytotoxic effect of the nanocomplexes was assessed in BMMΦ
primary cells and in HEK293T, L929 and HBMEC cell lines using a stan-
dard resazurin assay, as described elsewhere [1]. Brieﬂy, a monolayer of
BMMΦ (at a density of 3 × 104 cells/well), HEK293T and L929 (at a den-
sity of 1 × 104 cells/well) and HBMEC (at a density of 5 × 103 cells/well)
were incubated for 24 h (37 °C in a 5% CO2 atmosphere) with increasing
concentrations of free-AmB, Dex FD or SD and Dex-AmB FD or SD (0.78,
1.17, 1.76, 2.63, 3.95, 5.93, 8.89, 13.33 and 20 μM), previously sterilized
by ethylene oxide for 15 h at 53 °C ± 1 °C. After the incubation period,
10% (v/v) of a 2.5 mM resazurin solution was added to each well and
the cells were incubated at 37 °C in a 5% CO2 atmosphere for another
4 h. Fluorescence was measured (λex 560/λem 590) in a SpectraMAX
GeminiXS microplate reader (Molecular Devices LLC, California, USA).
Results were expressed as themean percentage± SD of viable cells rel-
atively to control condition (considered as 100% viability). The concen-
tration of a drug that kills half the BMMΦ cells (CC50) was calculated by
nonlinear regression analysis using the GraphPad Prism software. The
assay was performed in triplicate at least three times.Please cite this article as: R. Silva-Carvalho, J. Fidalgo, K.R. Melo, et al., Dev
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Bloodwas obtained from a healthy dog after owners' agreement and
collected to an EDTA tube. Whole blood was centrifuged (10 min at
1200 ×g, 4 °C) and the supernatant and buffy coat were discarded.
Red blood cells (RBCs)were resuspended in isotonic PBS pH 7.4. The pu-
riﬁed RBCs were counted using a Neubauer chamber and diluted to a
concentration of 1 × 108 cells/mL. Afterwards, 450 μL of RBCs were
placed in a 48-well plate containing 50 μL of AmB, Dex FD or SD, Dex-
AmB FD or SD (ﬁnal concentrations of 32, 16, 8, 4, 2 and 1 μM) and
the plates were incubated for 30 min at 37 °C under agitation
(120 rpm). After incubation, solutions were collected to eppendorfs
and centrifuged (10 min at 1200 ×g, 4 °C). The supernatants were col-
lected for analysis of the extent of hemolysis by reading the absorption
of the hemoglobin at 540 nm. Results were expressed as a percentage of
hemolysis with respect to the amount of hemoglobin released in the
presence of 1% of triton X-100,whichwas taken asmeasure of complete
(100%) lysis (Eq. (3)).
Hemolysis %ð Þ ¼ Abss−Absb
Abst−Absb
ð3Þ
Abss is the absorbance of the sample, Absb is the average absorbance
of the negative control, and Abst is the average absorbance of the lysed
samples. The assay was performed in triplicate at least three times.
2.4.7. Anti-Leishmania activity of the Dex-AmB nanocomplexes against
intramacrophagic amastigotes
BMMΦ were seeded in 96-well plates, at a cell density of
2 × 105 cells/mL. Subsequently, BMMΦ were infected with L. infantum
amastigotes at a multiplicity of infection (MOI) of 10 for 6 h. After the
infection period, non-internalized parasites were removed with com-
plete DMEM medium and infected cells were incubated for an addi-
tional 24 h. Increasing concentrations of free-AmB, Dex FD or SD, Dex-
AmB FD or SD (0.0039, 0.0078, 0.0156, 0.03125, 0.0625, 0.125, 0.25,
0.5, 1 μM) were added to the respective wells. After 24 h of incubation,
cell monolayers were ﬁxed with 4% (w/v) paraformaldehyde, perme-
abilized with 0.1% (v/v) Triton X-100 for 30 min at room temperature
and then stained with 4′,6-diamidino-2-phenylindole (DAPI) and with
high-content screening (HCS) CellMask™ Deep Red stain, which labels
parasite DNA and macrophages nucleus and cytoplasm, respectively.
The number of infected cells in each condition was determined in an
IN Cell Analyzer 2000 microscope (GE Healthcare, Illinois, USA) as de-
scribed by Gomes-Alves et al. [26]. Anti-Leishmania activity results
were expressed as themean percentage± SD of infected cells relatively
to the control. The IC50 concentration was calculated by nonlinear re-
gression analysis using the GraphPad Prism software. The assay was
performed in triplicate at least three times.
2.5. Statistics
Statistical analysis was performed using GraphPad Prism 5
(GraphPad Software, San Diego, CA, USA). Results were expressed as
mean ± SD. Two-way ANOVA followed by Bonferroni's multiple com-
parison post-test was performed wherever appropriate. Signiﬁcance
was considered as p b 0.05.
3. Results and discussion
3.1. Production and characterization of Dex-AmB nanocomplexes
The prepared nanocomplexes were ﬁrstly characterized in terms of
size, zeta potential andmorphology. Dex-AmB FD andDex-AmBSD pre-
sented a mean diameter of 214.2 ± 17.0 and 347.5 ± 36.1 nm, respec-
tively (Table 1). Size of nanomedicines is important as it inﬂuences
biodistribution and clearance. Small particles (b5–10 nm) tend to
have a reduced circulation time since they are rapidly cleared fromelopment of dextrin-amphotericin B formulations for the treatment of
Table 1
Average size, distribution and zeta potential of the Dex-AmB nanocomplexes dissolved in
dH2O. Results are expressed as mean ± SD.
Nanocomplex Size (nm)
Size distribution ζ potential
(mV)D10 D50 D90
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from 100 to 200 nm have been associated with increased phagocytosis
by Leishmania-infected macrophages [30]. Additionally, some studies
refer that nanoparticles larger than 200 nm are effective in targeting in-
fected macrophages [31]. Table 1 shows that the produced material is
polydisperse, presenting a wide size distribution. The size of the
nanocomplexes may be considered safe both for intralesional or intra-
venous injection, since capillary blockage and embolism is only pro-
moted by particles with size N5 μm [32]; it has been reported that
Fungizone®, which consist of particles with a mean size of 3310 nm
[33], can be applied without any harmful effects [34].
Themorphology of Dex-AmB FD and Dex-AMB SDwas examined by
Cryo-SEM (Fig. 1A and B) and SEM (Fig. 1C and D) (SEM analysis was
only possible to perform with Dex-AmB SD powder). As shown in
Fig. 1A and B, when in aqueous solution Dex-AmB FD and Dex-AMB
SD nanocomplexes have a spherical morphology, bearing a size consis-
tent with the previously referred size distribution analysis. This result
proves also that the rehydrated nanocomplexes are colloidally stable,
as no aggregates are observed. Moreover, Dex-AmB SD powderFig. 1. Representative Cryo-SEM microphotographs of (A) Dex-AmB FD and (B) Dex-AmB SD n
SEM microphotographs of Dex-AmB SD nanocomplex obtained at a magniﬁcation of (C) 10,00
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with some concavities (possible due to collapse upon drying), smooth
and non-porous surface. Similar results were obtained in another
study where cyclodextrin-AmB spherical amorphous solid microparti-
cles were prepared by spray drying [35]. The zeta potential of the Dex-
AmB FD and Dex-AmB SD nanocomplexes was found to be−13.67 ±
1.72 and−1.90 ± 0.21 mV, respectively (Table 1) whereas Dex, non-
charged glucose oligomers, has a zeta potential of−8.34 ± 2.71 mV.
Generally, when particles have a high surface charge (N|30 mV|), they
repel each other, which favors stability. In the current case, although
the particles observed by Cryo-SEM do not exhibit signs of aggregation,
the low zeta potential may compromise the long-term colloidal stability
in aqueous suspension. However, the dry formulation is easy to disperse
in water and to prepare just before use, thus the long-term stability in
aqueous suspension is not a pivotal feature.
The interaction of AmB with the polysaccharide was conﬁrmed
using different techniques, including FTIR, DSC, PXRD. Fig. 2 displays
the FTIR spectra, in the range of 700–4000 cm−1, for AmB, Dex FD,
Dex-AmB FD, Dex SD and Dex-AmB SD. Polysaccharide processing by
freeze- or spray-dryer did not cause any structural changes since all
characteristic peaks of the dextrin are observed. More speciﬁcally, a
strong and prominent absorption band at about 3386.7 cm−1 is ob-
served which can be assigned to -OH stretching vibrations. The
stretching of C\\H group vibrations and the -OH bending vibration is
observed at 2927.7 and 1639.3 cm−1, respectively and the absorption
bands at 1157.2 and 1026.0 cm−1 can be assigned to the stretching vi-
brations of C\\O and C\\C, and the bending mode of C\\H and
stretching vibration of C-O-C [36,37]. Regarding the spectra of AmB
crystals, it is possible to notice the absorption bands at 1558.3 and
1689.5 cm−1 which corresponds to the C_C stretching vibration fromanocomplexes in dH2O (magniﬁcation of 20,000×. Scale bars = 3 μm) and representative
0× (scale bar = 10 μm) and (D) 300,000× (scale bar = 4 μm).
elopment of dextrin-amphotericin B formulations for the treatment of
Fig. 2. FTIR spectra of (A) Dex and Dex-AmB processed by freeze-dryer and (B) Dex and Dex-AmB processed by spray-dryer, where is visible characteristic functional groups of AmB after
nanocomplexes production.
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respectively [38,39]. In addition, the peaks corresponding to C\\H
stretching (3012.5 cm−1), CH2 and CH3 symmetric stretching vibrations
(2877.5 cm−1), C-C-H (chromophore) bending as well as CH bending
(trans-polyene) (1010.6 cm−1), C_O asymmetric stretching vibrations
(1068.4 cm−1) and C\\H bending and CH3 rocking vibrations due to the
C_O asymmetric stretching vibrations (891.04 cm−1) are recognized
[40,41]. FTIR spectra of Dex-AmB FD (Fig. 2A) and Dex-AmB SD
(Fig. 2B) nanocomplexes are almost identical to their counterparts,
but they also present characteristic peaks of the AmB. More speciﬁcally,
both spectra feature the peaks corresponding to C_O and C_C
stretching vibration, that suffer a slight shift from 1689.5 and
1558.3 cm−1 to 1716.5 and 1569.9 cm−1, respectively, probably due
to the interaction with the polysaccharide. Similar results, where char-
acteristic peaks of AmB were still visible in the FTIR analysis, were re-
ported in the literature after drug conjugation to bovine serum
albumin (BSA) [38] or encapsulation in glutaraldehyde cross-linked
BSA microparticles [42], formation of AmB nano-assemblies with Aloe
vera leaf extract [43] and conjugation of AmB to oxidized sodium algi-
nate [19] or oxidized polymannose [22].
Thermal studies are useful to ascertain the compatibility, stability
and physical state of drugs conjugated to polymers or encapsulated inPlease cite this article as: R. Silva-Carvalho, J. Fidalgo, K.R. Melo, et al., Dev
Leishmaniasis, , https://doi.org/10.1016/j.ijbiomac.2020.03.019nanoparticles [36]. Fig. 3A and B shows the thermal behavior of AmB,
Dex FD, Dex-AmB FD, Dex SD and Dex-AmB SD in the range
25–235 °C. As described in the literature, AmB was characterized by a
double endothermic peak [39,44], here determined at 165.9 (melting
point of AmB crystal) and 199.5 °C whereas Dex FD (Fig. 3A) and Dex
SD (Fig. 3B) only showed a broad endothermic peak (152.4 °C and
162.2 °C, respectively). The almost complete disappearance of the
AmB endothermic peak was observed in the Dex-AmB FD (Fig. 3A)
and Dex-AmB SD (Fig. 3B) nanocomplexes. Kim et al. [39] also showed
that the incorporation of AmB in the cavities of the hydroxypropyl-γ-
cyclodextrin (HPγCD) promoted formation of an amorphous inclusion
complex, as concluded from the lack of the AmB endothermic peak.
Similar results were observed for conjugates of curcumin in dextrin
[36] and of AmB in pegylated poly(D, L-lactide-co-glycolide) (PLGA) co-
polymer nanoparticles [45]. These results were further conﬁrmed by
PXRD (Fig. 3C and D). Free-AmB in pure state presents a crystalline lat-
tice characterized by sharp peaks at diffraction angles of 2θ= 14.06,
17.26, 18.4, and 21.7, as reported elsewhere [39]. In the presence of
the polysaccharide, after freeze (Fig. 3C) or spray dying (Fig. 3D),
amorphization of the AmB is observed as characterized by the loss of
the drug characteristic peaks, being only visible a large diffraction
peak as in the processed free-polysaccharide. Similar results wereelopment of dextrin-amphotericin B formulations for the treatment of
Fig. 3.DSC curves (A andB) and X-ray powder diffraction (C andD) of free-AmB and (A, C) Dex, Dex-AmBnanocomplex processed by freeze-dryer and (B,D) Dex, Dex-AmBnanocomplex
processed by spray-dryer.
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successfully prepared through liquid antisolvent precipitation followed
by freeze-drying [46] and where AmB was encapsulated in polymeric
micelle of PLGA grafted-dextran copolymer [47] or incorporated in the
cavities of HPγCD [39]. Thus, we conclude that an amorphous inclusion
complex between the AmB and the dextrin chain networkswas formed.
3.2. Spectroscopic analysis of Dex-AmB nanocomplexes
UV–vis spectroscopywas used to investigate the aggregation state of
the AmB in its free form or in the nanocomplexes, after dispersion in
dH2O. It is known that the AmB aggregation state is a key factor with di-
rect impact on its cytotoxicity and activity [48,49]. In solution, AmBmay
exists in three forms: i) monomers, which is the soluble form, that
normally associates with ergosterol in fungal and protozoan cell
membranes; ii) oligomers (small soluble water aggregates; e.g.
Fungizone®), which can form pores in cholesterol-containing mem-
branes, leading to toxicity towards host cells [50]; and iii) poly-Please cite this article as: R. Silva-Carvalho, J. Fidalgo, K.R. Melo, et al., Dev
Leishmaniasis, , https://doi.org/10.1016/j.ijbiomac.2020.03.019aggregates [18,43], which is associated to lower in vitro and in vivo tox-
icity [51,52]. The UV–vis spectrum of AmB is very sensitive to aggrega-
tion and characterized by four well-separated bands when in a
monomeric state [53,54]. Moreover, the spectral modiﬁcations induced
by the extent of AmB aggregation can be represented by the ratio of the
ﬁrst to the fourth peaks, being a value of b1 characteristic of the mono-
meric form [38] and a value of N2 to a supper-aggregated form [43]. Our
results, showing four well-deﬁned peaks at approximately 349 (I), 369
(II), 387 (III) and 408 nm (IV), indicates that free-AMB exists in mono-
meric formwhen ﬁrstly dissolved in 0.1M borate buffer pH 11 and then
diluted in dH2O (Fig. 4). Furthermore, the peak I/IV (A349/A408) ratio for
the AmB dispersed in the aqueous solution was 0.4, conﬁrming its pres-
ence in monomeric form. This value is similar to the one obtained in a
study where AmB was dissolved in 50% methanol [54]. The dissolution
of the Dex-AmB FD nanocomplex (Fig. 4 – B) in dH2O promoted a
hypsochromic shift of the peak I to lower wavelength (335 nm), mean-
ing that the AmB in the nanocomplex acquired a water-soluble aggre-
gated form. In the case of the Dex-AmB SD nanocomplex (Fig. 4 – C),elopment of dextrin-amphotericin B formulations for the treatment of
Fig. 4. Study of AmB aggregation state by UV–vis spectroscopy. Changes in the
characteristic absorption peaks of AmB (at a ﬁnal concentration of 10 μM) in (A) its free
form (dissolved in 0.1 M borate buffer pH 11 and diluted in dH2O), (B) Dex-AmB FD
nanocomplex and (C) Dex-AmB SD nanocomplex (both dissolved and diluted in dH2O).
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concluded that the AmB in this material is also present in a water-
soluble aggregated form, since the UV–vis spectra of both
nanocomplexes are very similar. As referred above, AmB is highly
toxic in its aggregated state, promoting cytotoxicity [50]. For instance,
the highly toxic formulation Fungizone® dissolved in 5% dextrose has
a value of 2.9 [55]. For Dex-AmB FD (A335/A409) and Dex-AmB SD
(A348/A409) nanocomplexes the degree of AmB aggregation appears
not to be signiﬁcant since the ratio values were 1.13 and 1.11, respec-
tively. Furthermore, the higher the aggregation ratio, the lower the
amount of monomeric AmB present [53]. Therefore, our results enable
us to assume the presence of monomeric AmB in the nanocomplex,
which may attenuate the toxicity of the formulation.
3.3. AmB quantiﬁcation by HPLC-PDA-MS
The nanocomplexes were analyzed by HPLC using double detection
(PDA andMS). The overall yield values (%) are listed in Table 2. For Dex-
AmB FD, the overall yield (86.8%) is within the values reported for other
polysaccharide-AmB formulations (approximately 60–90%) [8,18–21].
Considering the Dex-AmB SD nanocomplex, a lower yield was achieved
(51.5%), as commonly reported in the development of spray dried phar-
maceuticals at the small scale used, regardless the improvements
achieved in the development of a nano spray dryer (ﬁnal product yields
increased theoretically to ±90%) [56].
While using spectrophotometry to assess the concentration of AmB,
as it is widely used in the literature [8,14,20,57],we noticed some lack of
reproducibility and consistency, probably due to differences on the ag-
gregation state. Therefore, an HPLC method was developed using a
Kinetex® C18 column. For the analyzed mass range of 923–925 m/z
and wavelength of 387 and 408 nm, linear regression in the range ofTable 2
Overall yield (%), AmB association efﬁciency (%) and drug content (% w/w) of Dex-AmB FD and
and UV detector (at 387 and 408 nm). *(n= 3).






Dex-AmB FD 86.8 14.68 ± 2.16 15.85 ± 0.61
Dex-AmB SD 51.5 14.38 ± 2.79 16.22 ± 0.83
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with r2 between 0.9983 and 0.9991 was obtained. The AmB content (%
w/w) and association efﬁciency (%) in the produced nanocomplexes
were estimated using both detection methods (Table 2). The AmB con-
tent results obtained are quite similar regardless of whether they are es-
timated using the UV or the MS detection method or of the type of
processing method used in the nanocomplexes production. As ex-
pected, comparatively to the freeze-dried material, the association efﬁ-
ciency determined for the spray-dried material is slightly inferior, since
the obtained yields are also lower.
In the literature reporting other polysaccharides- or synthetic
polysaccharide-based AmB formulations, AmB contents of 34.4, 36.6
and 32.9% were described for a dextran-AmB conjugate (amine),
dextran-AmB (imine) and dextran-AmB-ethanolamine (imine), respec-
tively [17], 23% and 26% for a arabinogalactan-AmB conjugates [8], 20%
for a galactomannan-AmB conjugate [21], 19.51% for AmB-
polymannose conjugates [22] and 18% for polyglucose-AmB conjugates
[23]. Similarly to ourwork,Mehenni et al. [35] produced in a spray dryer
a poly-γ-cyclodextrin-based AmB microspheres with a drug content of
13.72%. Even in works reporting AmB encapsulation in nanoparticles,
the drug content and/or association efﬁciency are in some cases slightly
superior or comparable to our results [34,47,53,54,57,58].
In this study, a Dex/AmB mass ratio of 4:1 was tested. However,
since the nanocomplex production process is extremely simple,without
any type of encapsulation or chemical modiﬁcation being performed,
increasing the drug content could be easily achieved by changing the
polysaccharide/drug mass ratio used at the beginning of the process.
Furthermore, the use of the spectrophotometric methods for drug con-
tent determination, a technique widely used in many of the above re-
ferred works, should be performed with caution as AmB UV–vis
spectra is very sensitive to modiﬁcations (as discussed in the
Section 3.2). This spectral instabilitymight inﬂuence thedetermined ab-
sorbance values decreasing the reproducibility and consistency of the
method and accuracy of the drug content determination.
3.4. In vitro cytotoxicity assays
Before testing the Dex-AmB formulations as a potential
leishmanicidal therapy approach, the associated intrinsic toxicity was
assessed. Thus, the cytotoxic effect of the free-AmB and of the different
formulations was assessed using a variety of cells. For this purpose, a
primary culture of BMMΦ and a kidney-derived HEK293T cell line (be-
cause AmB is associated with nephrotoxicity [59]) were employed.
Moreover, L929 (ﬁbroblasts) and HBMEC (endothelial) cell lines were
also used since the produced material is intended to be applied either
directly to a cutaneous lesion or intravenously.
As seen in Fig. 5 A and C, free-AmB was cytotoxic, in a dose-
dependent way, towards BMMΦ cells, reducing the cell viability to
levels under the 70% threshold (usually regarded as denoting cytotoxic
potential [60]) at concentrations between 1.76 and 2.63 μM (CC50 of
2.060 ± 0.186 μM; Fig. S1). Regarding the HEK293T cells (Fig. 5 B and
D), free-AmB also promoted a dose-dependent reduction of the cell vi-
ability at concentrations between 8.89 and 13.33 μM. These results
showing toxicity of AmB against the two types of cells described
above are in agreement with the literature. Toxic effects of AmB against
J774.2 or Raw 264.7 macrophage cell lines at concentrations aboveDex-AmB SD nanocomplexes obtained through HPLC, usingMS detector (at 923–925m/z)









14.85 ± 0.54 60 ± 8.83 64 ± 2.38 59 ± 2.17
15.35 ± 0.61 33 ± 5.24 34 ± 1.73 32 ± 1.27
elopment of dextrin-amphotericin B formulations for the treatment of
Fig. 5. Viability of (A and C) BMMΦ and (B and D) HEK293T cells after treatment with Dex-AmB nanocomplexes. Cell viability was evaluated by resazurin assay after treatment with
different doses of Dex-AmB FD (A and B) and Dex-AmB SD (C and D) for 24 h. Data is expressed as percentage relative to the control and presented as mean ± SD of three
independent experiments. Dex-AmB FD and Dex-AmB SD treatment conditions were compared with the AmB treatment condition using Bonferroni's multiple comparison post-test
(*p b 0.05, **p b 0.01 and ***p b 0.001).
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and THP1 and BMMΦ cells at 19.8 and 21.8 μg/mL, respectively [64]
were described in the literature. Gurudevan et al. [38] showed that
AmB at 15.6 μg/mL was highly cytotoxic against HEK293T cell line, pro-
moting N80% of cell death. In other studies, it was described that
7.8 μg/mL [22] or 10 μg/mL [19,23] of AmB promoted 50% or 90% of
HEK293T cells death, respectively. Considering the variability in the
doses of free-AmB that causes cytotoxicity, it is not surprising that our
results differ somewhat from those reported. On the other hand, at
the same concentrations, both Dex-AmB nanocomplexes were signiﬁ-
cantly less toxic against BMMΦ comparatively to the free drug. A reduc-
tion in cell viability to levels under the 70% thresholdwas only visible at
concentrations between 3.95 and 5.93 μM (Fig. 5 A and C) (CC50 of
5.77 ± 1.27 and 6.26 ± 1.96 μM for Dex-AmB FD and Dex-AmB SD, re-
spectively; Fig. S1). Fig. 5 B and D shows that none of the Dex-AmB
nanocomplexes promoted a reduction in HEK293T cell viability to levels
under the 70% threshold even at the highest dose tested.
The reduction of AmB toxicity after inclusion or conjugation to poly-
saccharides or encapsulation into polymeric nanoparticles was also re-
ported in the literature [19,23,38,39,53]. As expected, Dex was safe at
all the tested concentrations (Fig. 5), since it is generally recognized asPlease cite this article as: R. Silva-Carvalho, J. Fidalgo, K.R. Melo, et al., Dev
Leishmaniasis, , https://doi.org/10.1016/j.ijbiomac.2020.03.019safe (GRAS) and previously developed dextrin-based formulations did
not show cytotoxicity against BMMΦ and L929 cells [65,66]. Further-
more, the viability values above 100% seen for theDexmay be explained
by the cell growth stimulant character of dextrin [67]. The AmB inclu-
sion in the polysaccharide chain networks also allowed attenuating
the toxicity of the drug against L929 and HBMEC cell lines (Fig. S2).
The presented data appears to indicate that the Dex-AmB FD or Dex-
AmB SD nanocomplexes are safe and reduce the toxicity of AmB. Fur-
thermore, we speculate that in vivo the toxicity reduction may be even
more signiﬁcant as the nanocomplexes are expected to be swiftly inter-
nalized by the infected macrophages.
3.5. Hemolytic activity
Given that hemolysis is a severe side effect of AmB,we tested the he-
molytic potential of Dex-AmB FD and Dex-AmB SD at various concen-
trations (ranging between 1 and 32 μM). According to ASTM
E2524–08, materials resulting in over 5% hemolysis can be classiﬁed as
hemolytic [68]. Different works in the literature show that pure AmB
can lyse N70% RBCs at a concentration of 10 μg/mL (10.8 μM)
[19,38,53]. In this work, free-AmB was hemolytic towards dog RBCs atelopment of dextrin-amphotericin B formulations for the treatment of
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concentration (Fig. 6).
The inclusion of AmB into dextrin allowed a signiﬁcant decrease in
the hemolytic effect. In fact, Dex-AmB FD and Dex-AmB SD at 32 μM
promoted 61.5 ± 10.8% (nearly 1.58-fold less comparatively to free-
drug) and 57.7 ± 9.7% (nearly 1.69-fold less comparatively to free-
drug) of hemolysis, respectively, being the hemolytic activity negligible
(b5%) at 4 μM. This is consistent with ﬁndings of Zia et al. [43], who re-
ported that a simple formation of AmB nano-assemblies with Aloe vera
leaf extract decreased hemolysis of RBCs, even at 50 μg/mL AmB equiv-
alents. In other studies, signiﬁcant reduction of hemolysis to negligible
levels was shown after AmB encapsulation into PLGA [57,69], chitosan
[70] or polyglutamic acid [53] or conjugation to different polymers
such as arabinogalactan [14], sodium alginate [19], gum arabic [18],
dextran [17]. This outcome could be attributed to the shielding effect
of the polysaccharide onAmB [19].We tested also the hemolytic activity
of the processed polysaccharide and, as expected, negligible hemolysis
was observed even at the highest tested concentrations. Overall, our re-
sults suggest a wide safety margin of our nanocomplexes in blood-
contacting applications comparatively to the free-AmB and their suit-
ability for intravenous administration.
3.6. Anti-Leishmania activity against axenic promastigote and
intramacrophagic L. infantum amastigotes
Amphotericin B is active against both the extracellular promastigote
and intracellular amastigote forms promoting the formation of ionic
transmembrane channels, by the interaction with membrane ergosterol,
leading to parasite death [9,34]. In this study, the in vitro leishmanicidal
activity of AmB and Dex-AmB nanocomplexes was determined 24 h fol-
lowing exposure of L. infantum and L. amazonensis promastigotes or
BMMΦ infected with L. infantum amastigotes to different concentrations
of the above referred material. Regarding the axenic culture results
(Fig. 7 A and B), free-AmB was highly active against L. amazonensis and
L. infantum, with IC50 values of 0.028 ± 0.001 and 0.023 ± 0.010 μM, re-
spectively. Some results reported in the literature, although referring to
diverse species of Leishmania and presenting some variability, maintain
the same tendency. Petri e Silva et al. [71] described an IC50 value ofFig. 6. Percentage of hemolysis caused by AmB and Dex-AmB nanocomplexes upon their
interaction with dog RBCs with various concentrations (ranging between 1 and 32 μM)
for 30 min. Data is expressed as percentage relative to the control and presented as
mean ± SD of three independent experiments. Dex-AmB FD (*) and Dex-AmB SD (#)
treatment conditions were compared with the AmB treatment condition using
Bonferroni's multiple comparison post-test (*** and ### p b 0.001).
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other study using AmB, IC50 values from 0.01 to 0.27 μMwere reported,
being the promastigote L. mexicana the least sensitive strain (0.27 μM)
and L. donovani the most sensitive strain (0.012 μM) [72] of those tested,
effect thatwas also reported in another study [23]. Chávez-Fumagalli et al.
[73] reported IC50 values of 0.1 and 0.09 μg/mL for AmB-treated
L. amazonensis and L. infantum, respectively. On the other hand,
nanocomplexes also led to decreases in L. amazonensis and L. infantum vi-
ability, although at slightly higher concentrations comparatively to the
free-drug. In fact, when comparing the IC50 of our nanocomplexes to
free-AmB, it is noted that overall the latter has lower IC50. Dex-AmB FD
and Dex-AmB SD presented IC50 values of 0.056 ± 0.029 and 0.096 ±
0.050 μM, respectively, for L. amazonensis (Fig. 7 A) and of 0.030 ±
0.017 and 0.044 ± 0.025 μM, respectively, for L. infantum (Fig. 7B).
These differenceswere also observed in the literature for AmB conjugated
to dextran [17], gum arabic [18], among others polymers [20,23]. The ca-
pacity to accurately test in vitro anti-Leishmania activity against Leish-
mania-infected BMMΦ is a critical point in the development of new
formulations. For that, a protocol [26] for IN Cell Analyzer systemswas re-
cently developed and used here to obtain the dose-response curves for
the L. infantum tested with the formulations, as seen in Fig. 7C. Results
show that AmB displayed high activity against intramacrophagic
L. infantum parasites, as already reported in the literature [26,71,74].
Dex-AmB nanocomplexes had an activity similar to the free-drug, despite
the slightly higher IC50 values - 0.017 ± 0.009 and 0.023 ± 0.006 μM for
Dex-AmB FD andDex-AmB SD, respectively - promoting a decrease in the
amastigote parasite burden in the used concentration range. These results
are consistent with the literaturewhere reduced and unreduced AmB-AG
conjugateswere able to decrease the percentage ofmacrophages infected
with L. infantum (ED50 of 0.035 mg/mL and 0.027 mg/mL, respectively)
[75]. Importantly, the ﬁnding that Dex-AmB FD and Dex-AmB SD are ap-
proximately 2.47- and 1.98-fold more selective than free-drug is very
promising (Table 3) and proves that the inclusion of AmB into the poly-
saccharide chain networks applying the simple processing method de-
scribed in this work was able to improve the leishmanicidal potential of
the drug. Dextrin did not show any signiﬁcant effect, as expected, for all
the tested concentrations in both assays.4. Conclusions
The development of novel delivery systems for AmB to be used in
leishmaniasis treatment, that improves the therapeutic index of this
‘gold standard’ drug, has been pursued over the years. In this work,
we report a simple and economic formulation, where, unlike other
polysaccharide-AmB formulations reported in the literature, no chemi-
calmodiﬁcations or solvents are required. Both nanocomplexes are easy
to re-disperse in aqueous solutions and display leishmanicidal potential
against axenic cultures of promastigotes and against intramacrophagic
L. infantum amastigotes (selectivity index approximately 2.47- and
1.98-fold superior to the free-AmB). All the presented results strongly
suggest the Dex-AmB nanocomplexes have potential as a nanomedicine
for Leishmaniasis treatment since, in addition to the affordability and
simplicity of development, they are less toxic than other AmB based
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